Vitreo-retinal disease imaging with 3D annular-array ultrasound

使用 3D 环形阵列超声进行玻璃体视网膜疾病成像

• 批准号: 10289702
• 负责人: Jeffrey Ketterling
• 金额: $ 35.36万
• 依托单位: RIVERSIDE RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-22 至 2022-04-06
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10289702
• 关键词: 3-Dimensional; Acoustics; Adhesions; Agar; Age; Age related macular degeneration; Aging; Algorithms; Antioxidants; Area; Basic Science; Classification; Clinical; Collaborations; Collagen; Computer software; Data; Data Analyses; Data Collection; Degenerative Myopia; Detection; Development; Devices; Diabetes Mellitus; Diabetic Retinopathy; Diagnostic; Diagnostic Procedure; Disease; Disease Progression; Early Diagnosis; Early Intervention; Early treatment; Elements; Epidemic; Event; Eye; Family suidae; Gel; Genes; Goals; Growth; Hand; Head; Health; Heterogeneity; Image; Industrialization; Inner Limiting Membrane; Intervention; Investigation; Iris; Lateral; Life; Liquid substance; Low-Level Laser Therapy; Measures; Medical; Methods; Modification; Motion; Myopia; Optics; Pathology; Patients; Pharmacology; Phase; Posterior Vitreous Detachments; Posterior eyeball segment structure; Process; Property; Research; Resolution; Retina; Retinal Detachment; Risk; Saccades; Scanning; Sclera; Shapes; Site; Solid; Spatial Distribution; Structure; System; Technology; Traction; Translating; Ultrasonography; Vision; Visual; Vitrectomy; Vitreous Hemorrhage; Vitreous body structure; age related; base; computerized data processing; crosslink; curative treatments; design; disorder of macula of retina; experience; human subject; imaging system; improved; indexing; infancy; quantitative ultrasound; radio frequency; tool; validation studies; vitreous floater

Project Summary/Abstract The goal of this translational project is to add quantitative ultrasound (QUS) capabilities to a clinical ophthalmic ultrasound system in order to characterize vitreous inhomogeneity (i.e., clinically significant vitreous floaters re- ferred to as Vision Degrading Myodesopsia) as it relates to states of health and disease. Age-related changes due to collagen cross-linking and aggregation with liquefaction create inhomogeneities that appear non-uniformly throughout the vitreous body. For patients with myopia these processes occur earlier in life, when vitreo-retinal adhesion is still strong, and destabilize the vitreous body before adhesion to the retina is weakened, resulting in a variety of conditions that impact vision. The ability to depict vitreo-retinal organization will offer unique early stage detection and assessment of vitreo-retinal disease in patients with myopia at risk for retinal detachment and vitreo-maculopathies resulting from traction.. Currently, no diagnostic method is available to make data-based decisions related to the changes taking place in the vitreous body before blinding pathologies have developed. The impending epidemic of myopia has created an urgent clinical need for technologies offering objective and sensitive means for early detection of macromolecular changes and structural precursors in the vitreous body directly related to vitreo-retinal diseases. A diagnostic tool capable of quantitatively characterizing the entire vitreous body would assist in developing less invasive and affordable treatments for early intervention, such as pharmacologic vitreolysis or laser therapy, and for identifying patients in need of more aggressive interventions with vitrectomy. In collaboration with Quantel Medical, we will incorporate a new 3D probe and QUS capabilities into a state-of- the art, 20-MHz annular-array-based clinical ophthalmic ultrasound system. The early stages of the project will emphasize device enhancements to obtain necessary raw ultrasound data followed by age-normal and myopic patient data collection and development of QUS algorithms to characterize the vitreous body in 2D. The later stages of the project will focus on development and integration of a probe capable of volumetric acquisition, further patient data collection, and QUS classification methods that take advantage of the new volumetric data. The final system will permit quantitative characterization of the vitreous body and allow for data-based treatment decisions of vitreo-retinal diseases. While this investigation will focus on myopia, the resultant technology and approach will have the potential for application in many different clinical settings.

项目概要/摘要 该转化项目的目标是将定量超声 (QUS) 功能添加到临床眼科 超声系统，以表征玻璃体不均匀性（即临床上显着的玻璃体飞蚊症 被称为视力退化性肌病），因为它与健康状况和年龄相关的变化有关。 由于胶原蛋白交联和液化聚集产生不均匀性，看起来不均匀 对于近视患者来说，这些过程发生在生命的早期，即玻璃体视网膜。 粘附力仍然很强，并且在与视网膜的粘附力减弱之前使玻璃体不稳定，导致 描述玻璃体视网膜组织的能力将提供独特的早期结果。 有视网膜脱离风险的近视患者玻璃体视网膜疾病的分期检测和评估 以及牵引引起的玻璃体黄斑病变。 目前，没有可用的诊断方法来做出与发生的变化相关的基于数据的决策。 近视眼的流行造成了失明病症发生之前的玻璃体。 临床迫切需要为大分子早期检测提供客观、灵敏手段的技术 与玻璃体视网膜疾病直接相关的玻璃体变化和结构前体。 能够定量表征整个玻璃体的工具将有助于开发侵入性较小的和 早期干预的负担得起的治疗方法，例如药物玻璃体溶解术或激光治疗，以及识别 需要更积极的玻璃体切除术干预的患者。 与 Quantel Medical 合作，我们将把新的 3D 探针和 QUS 功能融入到一个状态中 该项目的早期阶段将开发基于 20 MHz 环形阵列的先进临床眼科超声系统。 强调设备增强以获得必要的原始超声数据，然后是年龄正常和近视数据 患者数据收集和 QUS 算法的开发，以二维表征玻璃体。 该项目的各个阶段将重点关注能够进行体积采集的探头的开发和集成， 进一步的患者数据收集，以及利用新体积数据的 QUS 分类方法。 最终系统将允许对玻璃体进行定量表征并允许基于数据的治疗 虽然这项调查将重点关注近视，但由此产生的技术和结果。 该方法将有可能应用于许多不同的临床环境。